Ajinomoto Adds Gene Therapy to CDMO Scope via $554M Forge Bio Buyout
Ajinomoto’s Forge Biologics acquisition brings contract development and manufacturing organization capabilities in gene therapy. Forge specializes in manufacturing AAV vectors used to deliver these therapies.